191 related articles for article (PubMed ID: 15068845)
1. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.
Ahmed SB; Bahloul C; Robbana C; Askri S; Dellagi K
Vaccine; 2004 Apr; 22(13-14):1631-9. PubMed ID: 15068845
[TBL] [Abstract][Full Text] [Related]
2. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
3. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
6. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
7. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Dumonteil E
Vaccine; 2005 Nov; 23(46-47):5372-9. PubMed ID: 16054271
[TBL] [Abstract][Full Text] [Related]
8. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
10. [Immuno-modulating effects of eukaryotic expressing vectors of IL-12 and GM-CSF associated to DNA-based vaccination against experimental cutaneous leishmaniasis in BALB/c mouse].
Ahmed SB; Dellagi K; Bahloul C
Arch Inst Pasteur Tunis; 2009; 86(1-4):39-50. PubMed ID: 20707219
[TBL] [Abstract][Full Text] [Related]
11. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
Dumonteil E; Andrade-Narvarez F; Escobedo-Ortegon J; Ramirez-Sierra MJ; Valencia-Pacheco G; Flores-Serrano A; Canto-Lara S; Arjona-Torres A
Dev Biol (Basel); 2000; 104():135-41. PubMed ID: 11713811
[TBL] [Abstract][Full Text] [Related]
13. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
Gurunathan S; Prussin C; Sacks DL; Seder RA
Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
[TBL] [Abstract][Full Text] [Related]
14. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
[TBL] [Abstract][Full Text] [Related]
15. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
16. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
Bolhassani A; Gholami E; Zahedifard F; Moradin N; Parsi P; Doustdari F; Seyed N; Papadopoulou B; Rafati S
Exp Parasitol; 2011 May; 128(1):9-17. PubMed ID: 21276444
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
[TBL] [Abstract][Full Text] [Related]
18. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major.
Chenik M; Louzir H; Ksontini H; Dilou A; Abdmouleh I; Dellagi K
Vaccine; 2006 Mar; 24(14):2521-9. PubMed ID: 16417957
[TBL] [Abstract][Full Text] [Related]
20. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines.
Carrión J; Folgueira C; Alonso C
Vaccine; 2008 Feb; 26(9):1155-65. PubMed ID: 18255202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]